New PTSD Treatment

We’re excited to announce that the FDA has granted priority review for a New Drug Application (NDA) for MDMA-assisted therapy for Post Traumatic Stress Disorder (PTSD). This development holds the potential to significantly transform mental health care, offering new hope to those unaffected by conventional treatments. TheraCover offers MDMA assisted therapy coverage, once federally approved.

Common medications have often proven insufficient in alleviating PTSD symptoms, highlighting the significance of promising results stemming from clinical trials evaluating MDMA-assisted therapy. Participants have commonly seen substantial decreases in PTSD symptoms, with many maintaining these positive outcomes long after their treatment.

It’s important to recognize the key contributions of mental health practitioners in providing this pioneering therapy. They need tailored malpractice insurance, equipped with added protections to offset risks associated with innovative treatments like MDMA-assisted therapy.

At AHT, we pride ourselves on providing comprehensive malpractice insurance solutions specifically tailored to therapists administering this innovative therapy. We’re committed to providing modern, effective solutions that encourage transparency in mental health care and promote lasting positive outcomes for patients. Our TheraCover policy form wording includes MDMA assisted therapy (when approved federally) under the definition of “professional services”. This makes it clear that our underwriters intend to cover this emerging form of treatment.

Being part of this transformative movement invigorates us. If you are incorporating these life-altering therapies into your practices, you can rely on us for comprehensive malpractice insurance coverage. Reach out to us today to explore our solutions and secure your peace of mind.